<DOC>
	<DOCNO>NCT00729482</DOCNO>
	<brief_summary>This phase II study evaluate RAD001 ( Everolimus ) term 4-month progression-free survival rate ( primary end-point ) response rate , toxicity , overall survival ( secondary end-points ) patient metastatic and/or advance inoperable gastric cancer . Eligibility criterion include histologically proven gastric/gastroesophageal junction cancer fail previous first-line standard treatment fluoropyrimidine platinum-based chemotherapy . Oral RAD001 ( everolimus ) 10mg daily administer dose adjust accord observed clinical toxicity . Treatment continue disease progression patient 's intolerability study drug . Total 54 patient enrol decide whether proportion patient free progression 4 month ( 16 week ) , P , less equal 0.15 great equal 0.30 ass treatment outcome 48 patient assume drop-out rate , 10 % .</brief_summary>
	<brief_title>RAD001 ( Everolimus ) Salvage Monotherapy Advanced Gastric Cancer ( AGC ) Who Failed Standard First-line Treatment</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Patients must histologically cytologically document stomach adenocarcinoma include adenocarcinoma esophagogastric junction Patients must nonresectable disease metastasis recurrent disease curative surgical resection unidimensionally measurable disease ( least long diameter 1 cm compute tomography scan , least 2 cm chest xray physical examination ) Patients tumor failure 1st line chemotherapy include fluoropyrimidine ( 5FU , capecitabine , doxifluridine , S1 , UFT ) platinum ( cisplatin , carboplatin , oxaliplatin ) palliative setting ; progression within 6 month chemotherapy Age 18 75 year old Estimated life expectancy 3 month ECOG performance status 2 low Adequate bone marrow function Adequate kidney function Adequate liver function No prior radiation therapy 25 percent BM Patients must psychological , familial , sociological geographical condition permit medical followup compliance study Women childbearing potential must negative pregnancy test admission The patient must able understand study give write informed consent participate study Other tumor type adenocarcinoma Central nervous system metastases prior radiation CNS metastasis Gastric outlet obstruction intestinal obstruction Evidence active gastrointestinal bleeding Bony metastasis sole evaluable disease Past concurrent history neoplasm stomach cancer Pregnant lactate woman , woman childbearing potential employ adequate contraception Thyroid disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>RAD001 ( everolimus )</keyword>
	<keyword>second-line treatment</keyword>
	<keyword>advanced gastric cancer</keyword>
</DOC>